SAB Biotherapeutics, Inc.
(NASDAQ: SABS)
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
4.022 -
+0.222
(+5.84%)
Range
4.022 - 4.450
(10.64%)
Open
4.100
Previous Close
3.800
Bid Price
4.020
Bid Volume
548
Ask Price
4.040
Ask Volume
270
Volume
1,056,993
Value
3,487,773
Remark
-
Delayed prices. Updated at 07 May 2026 22:51.
Data powered by
View All Events
Loading Chart...
Please login to view stock data and analysis
